Correlation between the presence of circulating tumor cells and the pathologic type and staging of non-small cell lung cancer during the early postoperative period

Xie,Zhanqiang; Gao,Xiaotian; Cheng,Keluo; Yu,Lishuang

doi:10.3892/ol.2017.6910

Correlation between the presence of circulating tumor cells and the pathologic type and staging of non-small cell lung cancer during the early postoperative period

Authors:
- Zhanqiang Xie
- Xiaotian Gao
- Keluo Cheng
- Lishuang Yu
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China, Department of Gastroenterology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China
Published online on: September 7, 2017 https://doi.org/10.3892/ol.2017.6910
Pages: 5825-5830
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study investigated possible correlations between the presence of circulating tumor cells (CTCs) and the pathologic types and staging of non-small cell lung cancer (NSCLC) during the early postoperative period. Sixty-nine patients with NSCLC were enrolled in the study. Clinical staging was performed by postoperative pathological examination and imaging. Multiple mRNA in situ analyses targeting specifically expressed genes were carried out to identify the presence of CTCs. Correlations between age, sex, TNM stage and pathological types with the detection rate of CTCs were also established. The results showed the positivity rate of CTCs in patients >55 years was significantly higher than that of patients <55 years (94.74 vs. 70.97%, P<0.05). There was no significant difference in the positivity rate of CTCs between male and female patients (85.71 vs. 85.29%, P>0.05). The correlations between the detection rate of epithelial type or mixed type CTCs with tumor size, lymph node metastasis and distant metastasis TNM in patients with NSCLC were not significant (P>0.05). However, higher TNM stages correlated with higher detection rates of mesenchymal CTCs (P<0.05). There were also significant differences in the detection rates of CTCs amongst the three different pathologic types (adenocarcinoma, squamous cell and large cell carcinomas) (P<0.05). Based on our results, the detection of mesenchymal CTCs during the early postoperative period can help prognosticate the recurrence and metastasis of NSCLC, which is beneficial to the development of individualized treatment strategies.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Woodard GA, Jones KD and Jablons DM: Lung cancer staging and prognosis. Cancer Treat Res. 170:47–75. 2016. View Article : Google Scholar : PubMed/NCBI
3	Jeon JH, Kang CH, Kim HS, Seong YW, Park IK, Kim YT and Kim JH: Video-assisted thoracoscopic lobectomy in non-small-cell lung cancer patients with chronic obstructive pulmonary disease is associated with lower pulmonary complications than open lobectomy: A propensity score-matched analysis. Eur J Cardiothorac Surg. 45:640–645. 2014. View Article : Google Scholar : PubMed/NCBI
4	Huang D, Fang F and Xu F: Hyperoxia induces inflammation and regulates cytokine production in alveolar epithelium through TLR2/4-NF-κB-dependent mechanism. Eur Rev Med Pharmacol Sci. 20:1399–1410. 2016.PubMed/NCBI
5	Zuo X, Zhang J, Zhang Y, Hsu SC, Zhou D and Guo W: Exo70 interacts with the Arp2/3 complex and regulates cell migration. Nat Cell Biol. 8:1383–1388. 2006. View Article : Google Scholar : PubMed/NCBI
6	Saygideğer-Kont Y, Minas TZ, Jones H, Hour S, Çelik H, Temel I, Han J, Atabey N, Erkizan HV, Toretsky JA, et al: Ezrin enhances EGFR signaling and modulates erlotinib sensitivity in non-small cell lung cancer cells. Neoplasia. 18:111–120. 2016. View Article : Google Scholar : PubMed/NCBI
7	Hong Y, Li Z and Zhang Q: A circulating tumor cell cluster-based model for tumor metastasis (Hypothesis). Oncol Lett. 12:4891–4895. 2016.PubMed/NCBI
8	Ilie M, Hofman V, Long E, Bordone O, Selva E, Washetine K, Marquette CH and Hofman P: Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med. 2:1072014.PubMed/NCBI
9	Reeh M, Effenberger KE, Koenig AM, Riethdorf S, Eichstädt D, Vettorazzi E, Uzunoglu FG, Vashist YK, Izbicki JR, Pantel K, et al: Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with EC. Ann Surg. 261:1124–1130. 2015. View Article : Google Scholar : PubMed/NCBI
10	Fusi A, Metcalf R, Krebs M, Dive C and Blackhall F: Clinical utility of circulating tumour cell detection in non-small-cell lung cancer. Curr Treat Options Oncol. 14:610–622. 2013. View Article : Google Scholar : PubMed/NCBI
11	Li H, Song P, Zou B, Liu M, Cui K, Zhou P, Li S and Zhang B: Circulating tumor cell analyses in patients with esophageal squamous cell carcinoma using epithelial Marker-Dependent and-Independent approaches. Medicine (Baltimore). 94:e15652015. View Article : Google Scholar : PubMed/NCBI
12	Zhang Z, Xiao Y, Zhao J, Chen M, Xu Y, Zhong W, Xing J and Wang M: Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer. Respirology. 21:519–525. 2016. View Article : Google Scholar : PubMed/NCBI
13	Lagerwaard FJ, Aaronson NK, Gundy CM, Haasbeek CJ, Slotman BJ and Senan S: Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol. 7:1148–1154. 2012. View Article : Google Scholar : PubMed/NCBI
14	Donato BM, Burns L, Willey V, Cohenuram M, Oliveria S and Yood MU: Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane and capecitabine: A descriptive report. Clin Ther. 32:546–554. 2010. View Article : Google Scholar : PubMed/NCBI
15	Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME and Meyer T: Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 31:365–372. 2013. View Article : Google Scholar : PubMed/NCBI
16	Stovold R, Blackhall F, Meredith S, Hou J, Dive C and White A: Biomarkers for small cell lung cancer: Neuroendocrine, epithelial and circulating tumour cells. Lung Cancer. 76:263–268. 2012. View Article : Google Scholar : PubMed/NCBI
17	Reijm EA, Sieuwerts AM, Smid M, Vries JB, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve CM, Jager A, et al: An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. BMC Cancer. 16:1232016. View Article : Google Scholar : PubMed/NCBI
18	Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 339:580–584. 2013. View Article : Google Scholar : PubMed/NCBI
19	Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC and Farace F: Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer. 105:1338–1341. 2011. View Article : Google Scholar : PubMed/NCBI
20	Hosokawa M, Yoshikawa T, Negishi R, Yoshino T, Koh Y, Kenmotsu H, Naito T, Takahashi T, Yamamoto N, Kikuhara Y, et al: Microcavity array system for size-based enrichment of circulating tumor cells from the blood of patients with small-cell lung cancer. Anal Chem. 85:5692–5698. 2013. View Article : Google Scholar : PubMed/NCBI
21	Catenacci DV, Chapman CG, Xu P, Koons A, Konda VJ, Siddiqui UD and Waxman I: Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound. Gastroenterology. 149:1794–1803.e4. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zhang Z, Shiratsuchi H, Palanisamy N, Nagrath S and Ramnath N: Expanded circulating tumor cells from a patient with ALK-positive lung cancer present with EML4-ALK rearrangement along with resistance mutation and enable drug sensitivity testing: A Case Study. J Thorac Oncol. 12:397–402. 2017. View Article : Google Scholar : PubMed/NCBI
23	Hyun KA, Kwon K, Han H, Kim SI and Jung HI: Microfluidic flow fractionation device for label-free isolation of circulating tumor cells (CTCs) from breast cancer patients. Biosens Bioelectron. 40:206–212. 2013. View Article : Google Scholar : PubMed/NCBI
24	Bystricky B, Jurisova S, Karaba M, Minarik G, Benca J, Sedlácková T, Tothova L, Vlkova B, Cierna Z, Janega P, et al: Relationship between circulating tumor cells and tissue plasminogen activator in patients with early breast cancer. Anticancer Res. 37:1787–1791. 2017. View Article : Google Scholar : PubMed/NCBI
25	Aieta M, Facchinetti A, De Faveri S, Manicone M, Tartarone A, Possidente L, Lerose R, Mambella G, Calderone G, Zamarchi R, et al: Monitoring and characterization of circulating tumor cells (CTCs) in a patient with EML4-ALK-positive non-small cell lung cancer (NSCLC). Clin Lung Cancer. 17:e173–e177. 2016. View Article : Google Scholar : PubMed/NCBI
26	Tsai WS, Chen JS, Shao HJ, Wu JC, Lai JM, Lu SH, Hung TF, Chiu YC, You JF, Hsieh PS, et al: Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci Rep. 6:245172016. View Article : Google Scholar : PubMed/NCBI
27	Chen X, Wang X, He H, Liu Z, Hu JF and Li W: Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS One. 10:e01262762015. View Article : Google Scholar : PubMed/NCBI
28	Swanson SJ, Miller DL, McKenna RJ Jr, Howington J, Marshall MB, Yoo AC, Moore M, Gunnarsson CL and Meyers BF: Comparing robot-assisted thoracic surgical lobectomy with conventional video-assisted thoracic surgical lobectomy and wedge resection: Results from a multihospital database (Premier). J Thorac Cardiovasc Surg. 147:929–937. 2014. View Article : Google Scholar : PubMed/NCBI
29	Ross K, Pailler E, Faugeroux V, Taylor M, Oulhen M, Auger N, Planchard D, Soria JC, Lindsay CR, Besse B, et al: The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer. Expert Rev Mol Diagn. 15:1605–1629. 2015. View Article : Google Scholar : PubMed/NCBI
30	Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, et al: Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 17:22015. View Article : Google Scholar : PubMed/NCBI